Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration

Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the p...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of biological markers 2005-04, Vol.20 (2), p.93-102
Main Authors: Riisbro, R, Christensen, I J, Nielsen, H J, Brunner, N, Nilbert, M, Fernebro, E
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since approximately 30% of patients with Dukes stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the preoperative plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) is associated with the survival of patients with early colo-rectal cancer. In this study we sought to confirm the independent prognostic value of suPAR in rectal cancer. suPAR was retrospectively determined by two different versions of a suPAR ELISA in preoperatively collected plasma samples from a Swedish (n=354) and a Danish (n=255) cohort of rectal cancer patients. In both cohorts the suPAR concentration was significantly higher in Dukes stage D patients than in Dukes stage A-C patients (p
ISSN:0393-6155
1724-6008
DOI:10.5301/JBM.2008.5473